Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center

(2012) Rodrigo Cartin-Ceba et al.   ARTHRITIS AND RHEUMATISM

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis

(2012) Rona M. Smith et al.   ARTHRITIS AND RHEUMATISM

Biologic agents in the treatment of granulomatosis with polyangiitis

(2012) U. SPECKS   CLEVELAND CLINIC JOURNAL OF MEDICINE

Genetically Distinct Subsets within ANCA-Associated Vasculitis

(2012) Paul A. Lyons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations

(2011) Julia U Holle et al.   ANNALS OF THE RHEUMATIC DISEASES

Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections

(2011) Daniel Tesfa et al.   ARTHRITIS AND RHEUMATISM

B-cell depleting agents for ANCA vasculitides: A new therapeutic approach

(2011) José A. Gómez-Puerta et al.   AUTOIMMUNITY REVIEWS

Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis

(2011) C. ROUBAUD-BAUDRON et al.   JOURNAL OF RHEUMATOLOGY

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

(2011) P. Emery et al.   RHEUMATOLOGY

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients

(2011) M Wendt et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis

(2010) Randi Y. Leavitt et al.   ARTHRITIS AND RHEUMATISM

Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

(2010) E. P. Rhee et al.   Clinical Journal of the American Society of Nephrology

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

(2010) R. F. van VOLLENHOVEN et al.   JOURNAL OF RHEUMATOLOGY

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis

(2009) Rachel B. Jones et al.   ARTHRITIS AND RHEUMATISM

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

EULAR recommendations for the management of primary small and medium vessel vasculitis

(2008) C Mukhtyar et al.   ANNALS OF THE RHEUMATIC DISEASES

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts

(2008) Christian Pagnoux et al.   ARTHRITIS AND RHEUMATISM